Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ruijin Hospital
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Provided signed and dated informed consent form.
Be male aged 18-80 years at consent.
Commit to protocol compliance and complete all study procedures.
Medically fit to tolerate interventions, including PSMA PET imaging, RARP, pelvic radiotherapy.
Diagnosis of localized intermediate/high-risk prostate cancer (miN0M0):
i. Confirmed by: systematic biopsy + PSA + PSMA PET/MRI. ii. Briganti nomogram (2017)≥7%. iii. Candidate for radical prostatectomy. iv. D'Amico:
1. Intermediate-risk: PSA 10-20ng/mL OR Gleason 7 (ISUP Grade 2/3) OR cT2b;
2. High-risk: PSA\>20ng/mL OR Gleason\>7 (ISUP Grade 4/5) OR cT2c.
You may not be if
Prior treatments for prostate cancer, including radiotherapy, chemotherapy or endocrine therapy.
Non-acinar adenocarcinoma histology on biopsy.
Preoperative evidence of metastasis: nodal(N1), locally advanced(T3-4), or distant(M1) disease on imaging.
History of pelvic lymphadenectomy or radiotherapy.
Other malignancies within 5 years.
Contraindications to radical prostatectomy or being deemed surgically inoperable upon clinical assessment.
Contraindications to radiotherapy or intolerance determined by radiation oncologists.
Severe allergy to PSMA PET ligands or excipients.
Any other conditions precluding PSMA PET examination.
Clareo Health | Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
